The new start-up QUANTRO Therapeutics at the Vienna BioCenter uses innovative transcriptome profiling technologies in a novel drug discovery pipeline to identify and develop effective anti-tumour therapeutics. The company is a spin-off resulting from the long-standing research cooperation between the institutes IMP and IMBA as well as the pharmaceutical company Boehringer Ingelheim and the Austrian Academy of Sciences. QUANTRO received a seed investment from the Boehringer Ingelheim Venture Fund and Evotec.
Cancer is a leading cause of death and one of the most complex challenges to modern medicine. The new startup QUANTRO Therapeutics employs cutting-edge technologies that precisely measure the effects of candidate targets and drugs on the fundamental cell process of transcription as a means of developing new drugs. By carrying out comparative analyses of such "transcription fingerprints", a completely new type of highly precise process for cell-based screens for new active ingredients. In the initial applications, QUANTRO is focusing on the discovery and development of chemical substances which interfere with cancer-associated transcription factors. This represents a class of particularly promising targets that have so far remained largely inaccessible for drug therapy.
Here you will get all the information you need about the topic of life sciences in Austria.